Prion protein inhibits fast axonal transport through a mechanism involving casein kinase 2

BURATTI, FIAMMA; SONG, YUYU; ZAMPONI, EMILIANO; BISBAL, MARIANO; CAICEDO, HECTOR HUGO; HELGUERA, PABLO R.; LADU, MARY J.; PIGINO, GUSTAVO F.; MA, JIYAN; CATALDI, GABRIEL; CATALDI, GABRIEL; BRADY, SCOTT T.; JUNGBAUER, LISA M.; JUNGBAUER, LISA M.; BURATTI, FIAMMA; LORENZO, ALFREDO; LORENZO, ALFREDO; SONG, YUYU; MORFINI, GERARDO A.; MORFINI, GERARDO A.; BISBAL, MARIANO; ZAMPONI, EMILIANO; HELGUERA, PABLO R.; CAICEDO, HECTOR HUGO; PIGINO, GUSTAVO F.; LADU, MARY J.; MA, JIYAN; BRADY, SCOTT T.

PLOS ONE

PUBLIC LIBRARY SCIENCE

Año: 2017 vol. 12 p. 1 - 24

1932-6203

Prion diseases include a number of progressive neuropathies involving conformational changes in cellular prion protein (PrPc) that may be fatal sporadic, familial or infectious. Pathological evidence indicated that neurons affected in prion diseases follow a dying-back pattern of degeneration. However, specific cellular processes affected by PrPc that explain such a pattern have not yet been identified. Results from cell biological and pharmacological experiments in isolated squid axoplasm and primary cultured neurons reveal inhibition of fast axonal transport (FAT) as a novel toxic effect elicited by PrPc. Pharmacological, biochemical and cell biological experiments further indicate this toxic effect involves casein kinase 2 (CK2) activation, providing a molecular basis for the toxic effect of PrPc on FAT. CK2 was found to phosphorylate and inhibit light chain subunits of the major motor protein conventional kinesin. Collectively, these findings suggest CK2 as a novel therapeutic target to prevent the gradual loss of neuronal connectivity that characterizes prion diseases.